115 related articles for article (PubMed ID: 32450304)
1. Development of a highly sensitive liquid chromatography-mass spectrometry method to quantify plasma leukotriene E
Löfgren L; Forsberg GB; Davidsson P; Eketjäll S; Whatling C
Prostaglandins Other Lipid Mediat; 2020 Oct; 150():106463. PubMed ID: 32450304
[TBL] [Abstract][Full Text] [Related]
2. Effect of zileuton and celecoxib on urinary LTE4 and PGE-M levels in smokers.
Mohebati A; Milne GL; Zhou XK; Duffield-Lillico AJ; Boyle JO; Knutson A; Bosworth BP; Kingsley PJ; Marnett LJ; Brown PH; Akpa EG; Szabo E; Dannenberg AJ
Cancer Prev Res (Phila); 2013 Jul; 6(7):646-55. PubMed ID: 23682075
[TBL] [Abstract][Full Text] [Related]
3. Urinary leukotriene E4 excretion is increased in type 1 diabetic patients: a quantification by liquid chromatography-tandem mass spectrometry.
Hardy G; Boizel R; Bessard J; Cracowski JL; Bessard G; Halimi S; Stanke-Labesque F
Prostaglandins Other Lipid Mediat; 2005 Dec; 78(1-4):291-9. PubMed ID: 16303623
[TBL] [Abstract][Full Text] [Related]
4. Determination of leukotriene E4 in human urine using liquid chromatography-tandem mass spectrometry.
Mizugaki M; Hishinuma T; Suzuki N
J Chromatogr B Biomed Sci Appl; 1999 Jun; 729(1-2):279-85. PubMed ID: 10410953
[TBL] [Abstract][Full Text] [Related]
5. Analytical and clinical validation of an LC-MS/MS method for urine leukotriene E4: A marker of systemic mastocytosis.
Lueke AJ; Meeusen JW; Donato LJ; Gray AV; Butterfield JH; Saenger AK
Clin Biochem; 2016 Sep; 49(13-14):979-82. PubMed ID: 26908217
[TBL] [Abstract][Full Text] [Related]
6. Direct injection method for quantitation of endogenous leukotriene E4 in human urine by liquid chromatography/electrospray ionization tandem mass spectrometry with a column-switching technique.
Kishi N; Mano N; Asakawa N
Anal Sci; 2001 Jun; 17(6):709-13. PubMed ID: 11707940
[TBL] [Abstract][Full Text] [Related]
7. Determination of LTE4 in human urine by liquid chromatography coupled with ionspray tandem mass spectrometry.
Wu Y; Li LY; Henion JD; Krol GJ
J Mass Spectrom; 1996 Sep; 31(9):987-93. PubMed ID: 8831151
[TBL] [Abstract][Full Text] [Related]
8. Tenidap inhibits 5-lipoxygenase product formation in vitro, but this activity is not observed in three animal models.
Carty TJ; Sweeney FJ; Griffiths RJ; Eskra JD; Ernest MJ; Pillar JS; Cheng JD; Loose LD; Joseph PA; Pazoles PP; Moore PF; Nagahisa A; Murase S; Kadin SB
Inflamm Res; 1997 May; 46(5):168-79. PubMed ID: 9197987
[TBL] [Abstract][Full Text] [Related]
9. Initial Clinical Experience with AZD5718, a Novel Once Daily Oral 5-Lipoxygenase Activating Protein Inhibitor.
Ericsson H; Nelander K; Lagerstrom-Fermer M; Balendran C; Bhat M; Chialda L; Gan LM; Heijer M; Kjaer M; Lambert J; Lindstedt EL; Forsberg GB; Whatling C; Skrtic S
Clin Transl Sci; 2018 May; 11(3):330-338. PubMed ID: 29517132
[TBL] [Abstract][Full Text] [Related]
10. Gas chromatographic-mass spectrometric determination of leukotriene E4 in human urine using deuterium-labelled leukotriene E4 standards.
Tsikas D; Fauler J; Gutzki FM; Röder T; Bestmann HJ; Frölich JC
J Chromatogr; 1993 Dec; 622(1):1-7. PubMed ID: 8120106
[TBL] [Abstract][Full Text] [Related]
11. Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation.
Carry M; Korley V; Willerson JT; Weigelt L; Ford-Hutchinson AW; Tagari P
Circulation; 1992 Jan; 85(1):230-6. PubMed ID: 1309444
[TBL] [Abstract][Full Text] [Related]
12. Validation and application of a new simple strategy for measurements of urinary leukotriene E4 in humans.
Kumlin M; Stensvad F; Larsson L; Dahlén B; Dahlén SE
Clin Exp Allergy; 1995 May; 25(5):467-79. PubMed ID: 7553251
[TBL] [Abstract][Full Text] [Related]
13. Enzymic preparation of dioxygen-18 labelled leukotriene E4 and its use in quantitative gas chromatography-mass spectrometry.
Tsikas D; Fauler J; Frölich JC
J Chromatogr; 1992 Feb; 574(2):181-7. PubMed ID: 1320043
[TBL] [Abstract][Full Text] [Related]
14. Development of an LC-MS method to quantify coproporphyrin I and III as endogenous biomarkers for drug transporter-mediated drug-drug interactions.
Njumbe Ediage E; Dillen L; Vroman A; Diels L; Kunze A; Snoeys J; Verhaeghe T
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jan; 1073():80-89. PubMed ID: 29241088
[TBL] [Abstract][Full Text] [Related]
15. Efficient method for the quantitation of urinary leukotriene E4: extraction using an Empore C18 disk cartridge.
Mita H; Oosaki R; Mizushima Y; Kobayashi M; Akiyama K
J Chromatogr B Biomed Sci Appl; 1997 May; 692(2):461-6. PubMed ID: 9188837
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, Pharmacodynamics, and Tolerability of AZD5718, an Oral 5-Lipoxygenase-Activating Protein (FLAP) Inhibitor, in Healthy Japanese Male Subjects.
Knöchel J; Nelander K; Heijer M; Lindstedt EL; Forsberg GB; Whatling C; Shimada H; Han DS; Gabrielsen A; Garkaviy P; Ericsson H
Clin Drug Investig; 2021 Oct; 41(10):895-905. PubMed ID: 34546534
[TBL] [Abstract][Full Text] [Related]
17. [Fundamental studies on the measurement of urinary leukotriene E4].
Oosaki R; Mizushima Y; Kawasaki A; Kobayashi M; Mita H; Maeda Y; Hayakawa T; Yamada T; Shida T
Arerugi; 1994 Feb; 43(2 Pt 1):127-33. PubMed ID: 8147715
[TBL] [Abstract][Full Text] [Related]
18. Leukotriene E4 elimination and metabolism in normal human subjects.
Sala A; Voelkel N; Maclouf J; Murphy RC
J Biol Chem; 1990 Dec; 265(35):21771-8. PubMed ID: 2174886
[TBL] [Abstract][Full Text] [Related]
19. Urinary leukotriene E4 concentrations as a potential marker of inflammation in dogs with inflammatory bowel disease.
Im Hof M; Schnyder M; Hartnack S; Stanke-Labesque F; Luckschander N; Burgener IA
J Vet Intern Med; 2012; 26(2):269-74. PubMed ID: 22268894
[TBL] [Abstract][Full Text] [Related]
20. Plasma levels of leukotriene E4 during clinical course of chronic obstructive pulmonary disease.
Shindo K; Hirai Y; Fukumura M; Koide K
Prostaglandins Leukot Essent Fatty Acids; 1997 Mar; 56(3):213-7. PubMed ID: 9089801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
